RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $295

Benzinga · 1d ago
RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform and lowers the price target from $297 to $295.